TB-500 (thymosin beta-4) and BPC-157 are both widely researched for their potential roles in recovery and tissue repair, but their dosing protocols are very different. TB-500 is typically studied at higher doses, often in the milligram range, taken less frequently (such as twice weekly) due to its longer systemic activity. BPC-157, on the other hand, is generally studied at much smaller microgram doses, administered daily or even multiple times per day, with research focusing on targeted healing effects.

Some peptide sellers attempt to “solve” the problem of combining these two compounds in one vial by adjusting ratios. For example, a common product on the market contains 5 mg of TB-500 and 5 mg of BPC-157 in a single vial. The idea is to make dosing easier, but in reality, it often leads to inaccurate administration. The volume required to get the correct dose of one peptide will almost always underdose or overdose the other, making precise, reproducible research impossible.

At Star-Bio, we don’t just try to sell you something—we care about doing things the right way. That means offering TB-500 and BPC-157 separately so researchers can follow proper protocols for each compound, ensuring accuracy, integrity, and meaningful results. Our approach isn’t about shortcuts; it’s about providing the highest quality products, correctly presented and dosed, so our customers can have full confidence in their research outcomes.

Doing it right isn’t just our policy—it’s the foundation of our reputation and our customer relationships.